DE3856072T2 - Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose - Google Patents

Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Info

Publication number
DE3856072T2
DE3856072T2 DE3856072T DE3856072T DE3856072T2 DE 3856072 T2 DE3856072 T2 DE 3856072T2 DE 3856072 T DE3856072 T DE 3856072T DE 3856072 T DE3856072 T DE 3856072T DE 3856072 T2 DE3856072 T2 DE 3856072T2
Authority
DE
Germany
Prior art keywords
polymorphe
epitheliale
humane
diagnosis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3856072T
Other languages
English (en)
Other versions
DE3856072D1 (de
Inventor
Joyce Taylor-Papadimitriou
Sandra Gendler
Joy Burchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878700269A external-priority patent/GB8700269D0/en
Priority claimed from GB878700279A external-priority patent/GB8700279D0/en
Priority claimed from GB878726172A external-priority patent/GB8726172D0/en
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Application granted granted Critical
Publication of DE3856072D1 publication Critical patent/DE3856072D1/de
Publication of DE3856072T2 publication Critical patent/DE3856072T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Surgical Instruments (AREA)
DE3856072T 1987-01-07 1988-01-07 Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose Expired - Lifetime DE3856072T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB878700269A GB8700269D0 (en) 1987-01-07 1987-01-07 Probe
GB878700279A GB8700279D0 (en) 1987-01-07 1987-01-07 Probe
US4130687A 1987-04-22 1987-04-22
GB878726172A GB8726172D0 (en) 1987-11-09 1987-11-09 Probe
PCT/GB1988/000011 WO1988005054A1 (en) 1987-01-07 1988-01-07 Probe

Publications (2)

Publication Number Publication Date
DE3856072D1 DE3856072D1 (de) 1998-01-02
DE3856072T2 true DE3856072T2 (de) 1998-03-12

Family

ID=27449866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856072T Expired - Lifetime DE3856072T2 (de) 1987-01-07 1988-01-07 Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Country Status (7)

Country Link
EP (3) EP0341252B1 (de)
JP (3) JPH02501828A (de)
AT (1) ATE160361T1 (de)
AU (1) AU1103988A (de)
CA (1) CA1339204C (de)
DE (1) DE3856072T2 (de)
WO (1) WO1988005054A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222509A (en) † 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
EP0369816A3 (de) * 1988-11-17 1990-09-12 The University Of Melbourne Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
JPH02255097A (ja) * 1989-03-29 1990-10-15 Ikuo Yamashina 単クローン抗体ｎｎｙ１２８
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
CA2040513A1 (en) * 1990-04-16 1991-10-17 Robert C. Bast, Jr. Method of diagnosing cancer
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU685539B2 (en) * 1993-12-24 1998-01-22 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antigen carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節
US6660714B1 (en) 1997-04-16 2003-12-09 Sloan Kettering Institute For Cancer Research α-O-linked glycoconjugates, methods of preparation and uses thereof
US7550146B2 (en) 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
WO2001014395A2 (en) 1999-08-20 2001-03-01 Sloan-Kettering Institute For Cancer Research Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
JP4276432B2 (ja) 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP1965190A1 (de) * 2007-02-27 2008-09-03 Qiagen GmbH Fixierung einer biologischen Probe
US20090035360A1 (en) 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
CN103140747B (zh) 2010-08-06 2015-07-15 Ykk株式会社 布料评价装置
EP3127919A4 (de) 2014-02-06 2017-08-16 Medicinal Chemistry Pharmaceuticals Co., Ltd. Antikörper gegen mucin 4 (muc 4)-glycopeptid und verwendung davon
CA3209579A1 (en) 2021-01-27 2022-08-04 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
EP0369816A3 (de) * 1988-11-17 1990-09-12 The University Of Melbourne Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper

Also Published As

Publication number Publication date
EP0823438A3 (de) 1999-09-15
CA1339204C (en) 1997-08-05
WO1988005054A1 (en) 1988-07-14
EP1103623A1 (de) 2001-05-30
JP2000333675A (ja) 2000-12-05
JPH02501828A (ja) 1990-06-21
EP0341252A1 (de) 1989-11-15
AU1103988A (en) 1988-07-27
DE3856072D1 (de) 1998-01-02
JPH10276773A (ja) 1998-10-20
ATE160361T1 (de) 1997-12-15
EP0341252B1 (de) 1997-11-19
EP0823438A2 (de) 1998-02-11

Similar Documents

Publication Publication Date Title
DE3856072T2 (de) Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
DE68929551D1 (de) Menschliche DNase
LU91005I2 (en) Dibotermine alfa
EP0375724A4 (en) Biologically active bactericidal/permeability-increasing protein fragments
DE69233011T2 (de) Rekombinante antikörper zur humanen therapie
IL88293A0 (en) Alveolar surfactant proteins
EP0398955A4 (en) Diagnosis of retinoblastoma
DK156592A (da) Human-h1-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet og fremgangsmaade til sammenfoejning af a- og b-kaederne i human-h1-relaxin
DE3482840D1 (de) Expressionsvektoren und deren verwendung zur herstellung eines proteins mit menschlicher alpha-antitrypsin-aktivitaet.
DE68917273T2 (de) Testmethode und Gerät zur Bestimmung des gesamten Proteins.
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
DE69940927D1 (de) PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDEr AKTIVITÄT
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
DE3878296T2 (de) Rekombinante menschliche glutathionperoxidase, verfahren zur herstellung des enzyms und dafuer kodierende dna.
DE3778375D1 (de) Reagenzsatz, seine verwendung und diagnostisches verfahren zur bestimmung von humanen pankreasspezifischen proteinen.
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
ATA259687A (de) Peptide mit einfluss auf die diurese und natriurese, diese enthaltende mittel und ihre verwendung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: IMPERIAL CANCER RESEARCH TECHNOLOGY LTD., LONDON,

8364 No opposition during term of opposition